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Article summary 
• The aim of this study was to investigate the mechanisms governing the 
aberrant nuclear localization of β-catenin in myeloid leukemia. 
• This study has characterized the first β-catenin interactomes for 
hematopoietic cells and identified the transcription factor LEF-1 as a driver of 
nuclear β-catenin localization in myeloid leukemia cells. 
Abstract 
Canonical Wnt/β-catenin signaling is frequently dysregulated in myeloid leukemias 
and is implicated in leukemogenesis. Nuclear-localized β-catenin is indicative of 
active Wnt signaling and is frequently observed in acute myeloid leukemia patients; 
however, some patients exhibit little or no nuclear β-catenin even where cytosolic β-
catenin is abundant. Control of the subcellular localization of β-catenin therefore 
represents an additional mechanism regulating Wnt signaling in hematopoietic cells. 
To investigate the factors mediating the nuclear-localization of β-catenin we carried 
out the first nuclear/cytoplasmic proteomic analysis of the β-catenin interactome in 
myeloid leukemia cells and identified putative novel β-catenin interactors. 
Comparison of interacting factors between Wnt-responsive cells (high nuclear β-
catenin) versus Wnt-unresponsive cells (low nuclear β-catenin) suggested the 
transcriptional partner, LEF-1, could direct the nuclear-localization of β-catenin. The 
relative levels of nuclear LEF-1 and β-catenin were tightly correlated in both cell lines 
and in primary AML blasts. Furthermore, LEF-1 knockdown perturbed β-catenin 
nuclear-localization and transcriptional activation in Wnt-responsive cells. 
Conversely, LEF-1 overexpression was able to promote both nuclear-localization 
and β-catenin-dependent transcriptional responses in previously Wnt-unresponsive 
cells. This is the first β-catenin interactome study in hematopoietic cells and reveals 
LEF-1 as a mediator of nuclear β-catenin level human myeloid leukemia. 
Key words: β-Catenin; Wnt Signaling; LEF-1; Myeloid; Leukemia; Interactome. 
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Introduction 
Canonical Wnt signaling is an evolutionary conserved signal transduction pathway 
strictly controlled during normal development but frequently dysregulated in cancer.1 
In the absence of a Wnt ligand, the central mediator of this signaling pathway, β-
catenin, is constitutively phosphorylated by a destruction complex (DC) consisting of 
GSK3β, CK1, Axin and APC, priming it for subsequent degradation by the 
proteasome. Upon Wnt ligand binding to the Wnt receptors (Frizzled and LRP5/6), 
the DC becomes saturated with phosphorylated β-catenin (which cannot be 
degraded) resulting in cytosolic accumulation of non-phosphorylated β-catenin.2 
Following nuclear translocation, β-catenin complexes with the T-cell factor 
(TCF)/lymphoid enhancer factor (LEF) transcriptional regulators and promotes 
activation of proto-oncogenic Wnt target genes like c-myc, cyclinD1 and survivin 
(http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). Thus, Wnt 
signaling activation is dependent on the movement of β-catenin into the nucleus, yet 
this remains a poorly understood process in blood cells. β-Catenin lacks canonical 
nuclear-localization or -export sequences and its subcellular distribution has instead 
been associated with multiple factors in context-dependent settings.3  
β-Catenin is frequently overexpressed in acute myeloid leukemia (AML)4 where its 
expression correlates with inferior patient survival.5 β-Catenin has been shown to 
play a key role in the initiation of AML and chronic myeloid leukemia (CML).6,7 
Furthermore, frequent chromosomal aberrations driving AML and CML are known to 
cooperate with β-catenin.8,9 Key to the activation of Wnt signaling is the movement of 
β-catenin into the nucleus and this is frequently observed in AML.10 We have 
previously demonstrated that around 10% of primary AML patient blast samples 
exhibit little nuclear β-catenin expression, despite substantial cytosolic levels, a 
phenomenon replicated in 10-20% of myeloid leukemia cell lines upon Wnt 
stimulation.3,11 In fact, this is characteristic of normal human hematopoietic 
stem/progenitor cells (HSPC) which similarly limit β-catenin nuclear-localization 
possibly to protect normal HSC from detrimental levels of Wnt signaling.12 The 
Morgan et al, 2019                           LEF-1 regulates β-catenin nuclear localization 
4 
 
permissive nuclear-localization of β-catenin observed in myeloid leukemias is 
therefore aberrant and warrants further investigation.  
To better understand β-catenin nuclear-localization mechanisms in myeloid leukemia 
cells, we generated the first β-catenin interactomes in hematopoietic cells. These 
analyses have shown that LEF-1, a β-catenin-dependent transcription factor, can 
also regulate the level of nuclear β-catenin in myeloid leukemia cells.  The relative 
level of nuclear LEF-1 expression correlates with relative nuclear levels of β-catenin 
in primary AML patient blasts indicating this axis has clinical relevance. Furthermore, 
the nuclear-localization of β-catenin can be promoted by LEF-1 overexpression and 
conversely is reduced by LEF-1 knockdown. Finally, we demonstrate LEF-1 
expression is suppressed in Wnt-unresponsive cells through rapid proteolytic 
degradation that is not observed in Wnt-responsive cells. Overall, this study 
characterizes β-catenin interactions within a hematopoietic context and identifies 
LEF-1 as a regulator of nuclear β-catenin localization in human leukemia. 
Methods 
Patient samples, cell culture and β-catenin stabilization 
Bone marrow, peripheral blood or leukapheresis samples from patients diagnosed 
with AML/MDS (Clinical information in Supplementary Table S1) were collected in 
accordance with the Declaration of Helsinki and with approval of University Hospitals 
Bristol NHS Trust and London Brent Research Ethics Committee. Mononuclear cells 
were separated using Ficoll-Hypaque (Sigma-Aldrich, Poole, UK) and samples with 
≥80% viability included in the study. K562, HEL, ML-1, U937, THP1 and PLB-985 
cell lines (ECACC, Salisbury, UK) were cultured as previously described.11 For 
proliferation assays cell lines were seeded in triplicate at 1x105/ml into 24-well plates 
within medium containing 10, 5, 1 or 0.5% fetal bovine serum (Labtech, East Sussex, 
UK) and cellular density counted using a hemocytometer at 24, 48 and 72 hours. For 
Wnt signaling activation, cell lines were treated with 5μM of the GSK-3β inhibitor 
CHIR99021 (Sigma-Aldrich) or 1μg/ml recombinant murine Wnt3a (Peprotech, 
London, UK) for 16hr (unless otherwise stated) at 37oC.  
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Nuclear/Cytoplasmic fractionation 
2-8x106 cells were washed in PBS and resuspended in 250μl cytoplasmic lysis buffer 
(10mM Tris-HCl (pH8), 10mM NaCl, 1.5mM MgCl2, 0.5% Igepal-CA630/NP40) 
containing complete™ Mini Protease-Inhibitor Cocktail (PIC; Sigma-Aldrich) for 10min 
at 4°C. The supernatant (cytosolic fraction) was recovered following centrifugation at 
800g for 5min, and the nuclear pellet washed twice with PBS. Nuclear pellets were 
resuspended in lysis buffer (Cell Signaling Technology, Leiden, Netherlands) 
containing PIC and incubated for 45min with sonication to maximize nuclear lysis. 
Insoluble material was removed at 21,000g for 10min and solubilized nuclear 
fractions stored at -80°C.  
Lentiviral transduction  
K562 and HEL cells were lentivirally-transduced with the β-catenin-activated reporter 
(BAR) or mutant ‘found unresponsive’ control (fuBAR) system as previously.11 For 
LEF-1 knockdown/overexpression, cells were lentivirally-transduced with human 
LEF-1 shRNA (TRCN0000-020163, -413476, -418104, -428178 and -428355, 
MISSION® Sigma), or LEF-1 overexpression vector (pLV-EGFP:T2A:Puro-
EF1A>hLEF-1 VectorBuilder, Neu-Isenburg, Germany). Cells transduced with 
scrambled shRNA/empty vector served as controls. 
β-catenin co-immunoprecipitation and immunoblotting 
For co-immunoprecipitation (co-IP), 8μg of crosslinked β-catenin (Clone-14) or IgG 
(Clone MOPC-31C) antibody (Becton Dickinson, Oxford, UK) were incubated with 
1mg of either pre-cleared cytoplasmic, or nuclear lysate, overnight at 4°C 
(Supplementary Methods). Subsequently beads were washed x5 prior to proteomic 
analyses or boiled for 95°C for 5min following washes for immunoblotting. 
Immunoblotting was performed as previously13 using antibodies to total β-Catenin 
(as above), phosphorylated β-catenin (Ser33/37/Thr41), α-Catenin (Clone-5), E-
Cadherin (Clone-36), GSK3β (Clone-7; BD), α-tubulin (DM1A), lamin A/C (4C11; 
Sigma), Axin1 (C76H11), Axin2 (76G6), TCF-4 (C48H11), LEF-1 (C12A5), Survivin 
(71G4B7), CyclinD1 (92G2; Cell Signaling Technology), active β-catenin (8E7, 
Merck-Millipore, Watford, UK) and c-MYC (9E10; Santa Cruz, Heidelberg, Germany). 
β-Catenin and LEF-1 densitometry were performed as described in Supplementary 
Methods.   
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Mass spectrometry (MS) and data analyses 
Cytosolic or nuclear β-Catenin/IgG co-IP’s were prepared and analyzed by MS as 
detailed in Supplementary Methods. Post-acquisition, duplicate values and proteins 
detected by only a single peptide were first removed. Tandem Mass Tag (TMT) 
ratios were imported into Perseus v1.5.6.0 (Max Planck Institute of Biochemistry, 
Munich, Germany) followed by logarithmic transformation, normalization (through 
median subtraction) and removal of proteins not present in at least 2 of 3 replicates. 
A one-sample t test was performed with significance of protein binding (-Log10 p 
value) plotted versus fold change in protein binding (Log2). The MS proteomics data 
have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with 
the dataset identifier PXD009305. Interaction specificity was assessed using the 
publicly available CRAPome database (Contaminant Repository for Affinity 
Purification: http://www.crapome.org). 
Assessment of TCF reporter and flow cytometry 
Activity of BAR lentiviral construct was performed as previously.11 Multi-parameter 
flow cytometric measurements were acquired using a MACSQuant® Analyzer 10 in 
conjunction with MACSQuantify™ v2.8 (Miltenyi Biotec, Bisley, UK) or an Accuri C6 
in conjunction with C sampler software v1.0.264.21 (BD). Post-acquisition analyses 
were performed using FlowJo v10.5.3 (Tree Star Inc, Ashland, OR). Threshold for 
TCF reporter fluorescence was set using matched-controls expressing mutant ‘found 
unresponsive’ fuBAR. Cell viability was assessed using 2μg/mL propidium iodide 
(Miltenyi Biotech).  
Statistics 
Statistical analyses were performed using GraphPad Prism v7.0 (GraphPad 
Software Inc., San Diego, CA) and Perseus. Correlation was assessed using a 
Spearman’s Rank correlation coefficient (R). Significance of difference was 
assessed using a one-sample or Students’ t test and data represents mean±1 SD 
derived from three biological replicates. 
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Results  
Myeloid leukemia cell lines exhibit heterogeneous nuclear β-catenin localization and 
Wnt activation 
Previously we showed that myeloid leukemia cell lines vary markedly in their 
capacity for nuclear β-catenin localization upon Wnt stimulation, mimicking the 
heterogeneity of nuclear β-catenin translocation in AML patients.11 To investigate the 
mechanistic basis for this, we selected two sets of myeloid leukemia lines which 
differed markedly in Wnt signaling output in response to agonist. K562 and HEL 
were Wnt-responsive cell lines that localized high levels of β-catenin into the nucleus 
upon treatment with the Wnt agonist, CHIR99021, a GSK3β inhibitor (Figure 1A). 
Cell viability was not significantly affected by 16hr CHIR99021 treatment 
(Supplementary Figure S1AB). Similar patterns of subcellular localization were 
observed for the active (non-phosphorylated) form of β-catenin in response to 
CHIR99021 (Supplementary Figure S1C). As expected, the phosphorylated forms of 
β-catenin (Ser33/37/Thr41) were reduced upon CHIR99021 treatment 
(Supplementary Figure S1C). Correspondingly these lines showed robust induction 
of a TCF reporter (a measure of β-catenin-dependent transcription), whilst cells 
expressing reporter with a mutated TCF binding site showed no induction (Figure 
1B). In contrast, ML-1 and U937 cells had a highly restricted capacity for nuclear β-
catenin localization (versus K562 and HEL cells) despite substantial cytosolic 
stabilization of the protein (Figure 1B and C). Consistent with this, CHIR99021 
treatment of ML-1 or U937 cells caused no detectable activation of the TCF reporter 
(Figure 1B and 1D). The same patterns of Wnt-responsiveness were observed when 
cell lines were treated with rWnt3a (Supplementary Figure S2). These findings 
demonstrate that the ability of some leukemia cells to drive a transcriptional 
response to Wnt agonist is limited by their capacity to permit the nuclear 
accumulation of β-catenin and we termed these cells Wnt-unresponsive. 
β-Catenin interactome analyses reveal contrasting protein interactions between Wnt-
responsive and Wnt-unresponsive leukemia cell lines 
Given the wealth of factors previously reported to regulate the nuclear localization of 
β-catenin,3 we designed an interactome screen of cytosolic and nuclear β-catenin 
interacting partners from representative Wnt-responsive (K562 and HEL), and Wnt-
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unresponsive (ML1) cell lines so that we could shortlist candidate factors involved in 
this process (Figure 2A). Prior to mass spectrometry, we validated the efficiency of 
β-catenin co-immunoprecipitation (co-IP) (Figure 2B) from both a positive control for 
high β-catenin expression (SW620 colorectal cells containing mutated APC: 
demonstrating a 4.0- and 4.3-fold enrichment of β-catenin in cytosol and nuclear 
fractions respectively) and in the context of agonist-stabilized β-catenin (HEL: 
showing a 6.3- and 9.1-fold enrichment). We also confirmed co-IP of a known 
interactor; TCF-4 (TCF7L2) from the nuclear compartment.  
Following mass spectrometry, raw tandem mass tag (TMT) ratios were processed to 
generate a set of statistically ranked interactions based on significance of fold-
change in protein binding (raw and processed MS data available in Supplementary 
MS Data Excel sheets). An extensive profile of β-catenin interactions were observed 
in K562 cells (225 significantly enriched cytosolic interactions, 118 significantly 
enriched nuclear interactions; Figure 3A and 3B). In contrast, a comparatively sparse 
interaction profile was observed in ML1 cells (38 significantly enriched cytosolic 
interactions, 26 significantly enriched nuclear interactions; Figure 3C and 3D). An 
extensive repertoire of β-catenin interactions was also detected in the other Wnt-
responsive cell line analyzed, (HEL; 154 significantly enriched cytosolic interactions, 
138 significantly enriched nuclear interactions; Supplementary Figure S3). The 
sparse nuclear β-catenin interaction network observed in ML1 cells is perhaps 
unsurprising given the low levels of nuclear β-catenin, however the relative paucity of 
interactors observed in the cytosol of this line was more surprising given the 
comparable abundance of β-catenin in this fraction compared with K562/HEL cells.  
Our experimental and bioinformatics strategy was validated by the identification of 
known β-catenin interactions (highlighted in green), which were also more abundant 
in the K562 cells (23 in cytosol, 26 in nucleus) versus the ML-1 cells (7 in cytosol, 8 
in nucleus). From our significantly enriched interactions (red dots; Figure 3 panels), 
we identified several putative novel partners for β-catenin as summarized for K562 
(Figure 4A, B and Supplementary Table S2), ML1 (Figure 4C, D and Supplementary 
Table S2), and for HEL (Supplementary Figure S4 and Supplementary Table S3). 
Within these significant interactions we identified a number of novel associations of 
particular interest to myeloid leukemias and/or Wnt signaling which appeared in one 
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or more cell lines (red asterisks), but were outside the remit of this study to 
investigate further. MBD3 and PRC1 have been found to cooperate with the 
oncogenic fusion proteins PML/RARα14 or PLZF/RARα15 in acute promyelocytic 
leukemia (APL), and regulate stemness through Wnt/β-catenin signaling.16,17 The 
RNA binding protein MSI2 predicts poor prognosis in AML,18 more aggressive 
CML,19 and can promote cancer via Wnt signaling.20 LIN28B, a microRNA-binding 
protein, is overexpressed in multiple leukemias including AML,21 where it promotes 
proliferation,22 and cooperates with Wnt signalling to drive malignancy.23 DDX10, 
RBM6 and RBM15 are known to form oncogenic fusion proteins in myeloid 
leukemias,24-26 and DDX10 and RBM15 also have roles in promoting Wnt 
signaling.27,28 PUM2 and MKRN2 are two further proteins reported to promote the 
growth of both normal and malignant hematopoietic cells.29,30 We also confirmed the 
first reported β-catenin interaction with Wilms Tumour-1 (WT1) by MS and 
immunoblotting (Supplementary Figure S5), which is of considerable interest in 
leukemia biology given its frequent dysregulation in AML and association with 
adverse patient survival.31  
Nuclear LEF-1 expression correlates with nuclear β-catenin localization in cell lines 
and primary AML patient cells 
We next examined the data from the fractions of Wnt-responsive cells for candidate 
proteins that could promote the nuclear-localization of β-catenin. Several had 
previously been implicated in negative regulation of β-catenin nuclear localization: 
GSK3β,32 α-catenin,33 Axin1/2,34 and APC34; whilst TCF-434 and LEF-135 are nuclear 
localized transcription factors that bind β-catenin. To validate the MS data, we 
examined the protein expression of these candidates in a panel of myeloid cell lines 
by immunoblotting. With the exception of APC (which is problematic to blot)36 
immunoblotting confirmed MS analysis in that expression of the negative regulators 
was mostly limited to Wnt-responsive cells making it unlikely they were responsible 
for restricted nuclear β-catenin in Wnt-unresponsive cells (Figure 5A).   
We next examined the expression of two known nuclear β-catenin interactors, TCF-4 
and LEF-1, which are ubiquitously expressed in multiple tissues.  Both of these 
proteins are predominantly nuclear in Wnt-responsive cell lines and were absent 
from the Wnt-unresponsive lines (Figure 5A; matching the proteomics data in Figure 
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3 and also Supplementary Figure S3). Of these two proteins, LEF-1 bound β-catenin 
with higher significance than TCF4 in both K562 and HEL nuclei. This, together with 
our previous observation that overexpression of TCF-4 actually suppressed β-
catenin-dependent transcription37 (and thus is unlikely to promote nuclear β-catenin 
level) led us to focus our investigation on LEF-1. This protein is known to be 
dysregulated in AML38 so we examined the clinical relevance of this by correlating 
relative LEF-1 nuclear localization with that of β-catenin in primary AML blasts. In our 
cohort of 23 nuclear/cytosol fractionated AML patient samples we observed a highly 
significant degree of correlation (Spearman Rank R=0.63, P<0.005) between the 
relative nuclear-localized (as a proportion of total) β-catenin protein and relative 
nuclear-localized (as a proportion of total) LEF-1 protein (Figures 5B and C). 
Interestingly, the overall frequency of β-catenin protein expression observed in this 
largely pediatric AML cohort was higher than previous reports (Supplemental Figure 
S6). Taken together, these data indicate that nuclear β-catenin translocation capacity 
is linked to LEF-1 expression in myeloid cell lines, and nuclear LEF-1 is a strong 
clinical predictor of nuclear β-catenin levels in patient-derived AML blasts. 
Modulation of LEF-1 expression in myeloid cells regulates nuclear-localization of β-
catenin and alters Wnt-responsiveness. 
The above data indicated a correlative relationship between nuclear LEF-1 level and 
capacity for nuclear β-catenin localization. To demonstrate causation, we examined 
the effect of modulating LEF-1 expression on β-catenin localization. Initially, we 
tested multiple LEF1 shRNA sequences (Supplementary Figure S7A) and selected 
the most optimal (TRCN0000428355) for knockdown of nuclear LEF-1 expression in 
the Wnt-responsive K562 and HEL cell lines. This approach resulted in a 72%±7% 
knockdown in LEF-1 protein in the nuclei of K562 cells and an 89%±4% knockdown 
in HEL cells (Figure 6A). Somewhat lower levels of LEF-1 knockdown were observed 
in CHIR99021-treated cells (65%±19% and 83%±7%, respectively) probably a result 
of LEF1 being a Wnt target gene and thus being induced through Wnt agonist 
treatment.39 LEF-1 knockdown perturbed nuclear localization of β-catenin by 
approximately a third (28%) in K562 following CHIR99021 treatment, proportionate 
to control cells. This reduction was accentuated in HEL cells (41%) which 
corresponded to the greater degree of LEF-1 knockdown in these cells (Figure 6B). 
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The knockdown of LEF-1 protein resulted in significantly reduced growth of both 
K562 and HEL cells at multiple timepoints across a range of serum concentrations 
(Figure 6C). Use of a second LEF1 shRNA and a different method of Wnt stimulation 
(rWnt3a) resulted in a similar finding (Supplementary Figure S7B and C). These data 
suggest LEF-1 promotes the optimal translocation of β-catenin into the nucleus of 
Wnt-responsive cells and contributes partly to their growth. 
Next, we examined whether LEF-1 expression was sufficient to permit nuclear-
localization of β-catenin. To establish this, we stably overexpressed LEF1 in the Wnt-
unresponsive (and LEF-1 negative) U937 and ML1 cells. Overexpression of LEF-1 
resulted in substantial cytosolic expression of the full-length LEF-1 protein (50kDa) 
but weak nuclear expression; despite this we observed a dramatic increase in 
nuclear localized β-catenin in both ML1 (4-fold) and U937 (2.3-fold) cells 
overexpressing LEF1 following CHIR99021 treatment (Figure 6D and E). This 
disparity may be explained by the abundant expression of a short-form of LEF-1 in 
the nucleus (25-30kDa) that was absent in Wnt-responsive lines (discussed below). 
These effects were mirrored using Wnt3a treatment (Supplementary Figure S7C) 
and we also showed that LEF-1 overexpression was able to facilitate nuclear 
localization of β-catenin in two further AML cell lines (PLB-985 and THP1; 
Supplementary Figure S7D). These data demonstrate that overexpression of LEF-1 
can significantly increase the capacity for nuclear β-catenin localization in Wnt-
unresponsive cell lines. 
To assess the impact of LEF-1 knockdown (and subsequent nuclear β-catenin 
reduction) on Wnt signaling, we measured TCF reporter activity. As predicted, Wnt 
signaling induction in Wnt-responsive K562 and HEL cells following CHIR99021 
treatment was severely diminished following LEF-1 knockdown (Figures 7A and B). 
A significant reduction in Wnt signaling output was also observed following use of an 
alternative LEF1 shRNA in response to CHIR99021 or Wnt3a stimulation 
(Supplementary Figure S8). Assessment of the TCF reporter activity in the LEF1 
overexpressing lines was not possible due to the confounding expression of the GFP 
selectable marker; instead we examined the protein expression of the classic 
downstream Wnt target proteins survivin, c-MYC and cyclinD1. We found that LEF1 
overexpression significantly enhanced the expression of these proteins following 
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CHIR99021 treatment (Figure 7C and D), indicating that the observed translocation 
of β-catenin was sufficient to generate a transcriptional response. A caveat to these 
data is that these observations cannot be linked exclusively to the modulation of β-
catenin nuclear-localization since LEF-1 expression is a co-variable in these 
experiments. Taken together, these data indicate LEF-1 can regulate the nuclear 
level of β-catenin and our observations are also consistent with a concomitant 
regulation of Wnt signaling activity. 
LEF-1 protein is proteolytically cleaved in Wnt-unresponsive cells 
In the experiments above, overexpression of full-length LEF-1 in Wnt-unresponsive 
cell lines resulted in the emergence of a 25-30kDa species of LEF-1 protein. To 
evaluate the contribution of this short LEF-1 form with the increased nuclear β-
catenin level observed in these cell lines we examined the β-catenin binding capacity 
of this species. We performed β-catenin co-IP from both the cytosol and nucleus of 
CHIR99021 treated LEF1-overexpressing U937 cells and immunoblotted for LEF-1 
protein. As observed in Figure 8A, both the full-length and short-forms of LEF-1 
protein co-IP’d with β-catenin from the cytosol implying both forms bind β-catenin in 
this cell line. In the nuclear fraction, β-catenin preferentially co-IP’d with the short 
LEF-1 form, though the proportion of short-form was highly enriched in this fraction 
(Figure 8A; input lane). These data confirm that the short-form LEF-1 has β-catenin 
binding ability and could mediate the increased nuclear β-catenin translocation 
observed in Wnt-unresponsive cell lines above upon LEF-1 overexpression with 
CHIR99021 treatment. 
Finally, we examined the origin of the short LEF-1 polypeptide. This variant was 
unlikely derived from alternative splicing since the ectopic expression of LEF-1 was 
driven from cDNA. Furthermore, these short forms of LEF-1 were also observed 
endogenously in colorectal cell lines (Supplementary Figure S9A) and in primary 
AML samples featured in Figure 5 (full blots in Supplementary Figure S9B). 
Therefore, the presence of short-form LEF-1 was most consistent with a proteolytic 
cleavage mechanism. To investigate this, nuclear lysates from both K562 control and 
U937-LEF1 cells ± protease inhibitor cocktail (PIC) were incubated at 37oC and the 
relative proportions of full-length to short LEF-1 forms in each cell line observed over 
0-60 minutes. In K562 control cells, full-length LEF-1 protein was stable with no 
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detectable breakdown of full-length LEF-1 protein even in the absence of PIC (Figure 
8B). In contrast, the full-length LEF-1 band present in U937-LEF-1 cells was reduced 
with concomitant enrichment of the short-form polypeptide after a 10 min incubation 
at 37°C (Figure 8C). The removal of the PIC reduced the half-life of full-length LEF-1 
by approximately 50% with degradation occurring within 5 min. Together these data 
are consistent with the short-form of LEF-1 arising through proteolytic processing. 
These data suggest that LEF-1-targeted proteases are active in Wnt-unresponsive 
U937 cells, but inactive/absent in Wnt-responsive K562 cells. To test this, we mixed 
nuclear lysates from K562 cells directly with whole cell lysates from U937 control 
cells (which are LEF-1 negative). Remarkably, the previously stable full-length LEF-1 
band present in K562 cells exhibited marked and rapid reduction with a concomitant 
increase in the short-form polypeptide, a process exacerbated by PIC removal 
(Figure 8D). These data confirm that constitutive LEF-1 degradation mechanisms are 
active in Wnt-unresponsive cells but are absent/inhibited in Wnt-responsive cells.   
Discussion 
Canonical Wnt signaling has emerged as one of the most frequently dysregulated 
signaling pathways in myeloid neoplasms which has led to considerable interest in 
targeting this pathway. The central mediator β-catenin represents an appealing 
therapeutic target because of its leukemogenic role,6,7 prognostic influence5 and 
functional redundancy in normal hematopoietic development.40 The characterization 
of β-catenin’s hematopoietic interactome is therefore of considerable interest and the 
experimental approach adopted in this study was validated by the identification of 
multiple known β-catenin partners such as Axin, TCF-4, α-catenin and APC. 
Associations with key hematopoietic transcription factors, C/EBPζ and GATA-1, 
were identified and these are known to co-occupy genomic sites with TCF-4 (a 
known β-catenin partner) during hematopoietic development.41 We confirmed the 
previously reported interaction of β-catenin with the oncogenic fusion protein BCR-
ABL in CML, which is present in K562 cells.9 In addition to known partners, we 
identified putative novel interactions which have known relevance to leukemia and/or 
Wnt signaling (MBD3,14,16 PRC1,15,17 MSI2,18-20 LIN28B,21-23 DDX10,24,27 RBM6,25 
RBM15,26,28 PUM2,29 MKRN230 and WT131).  
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For investigating β-catenin nuclear localization mechanisms we focused on LEF-1 
given that it was one of the most significantly enriched interactors present in Wnt-
responsive cell nuclei, and its nuclear expression was highly predictive of β-catenin 
nuclear-localization in both myeloid cell lines and primary AML blasts. A role for LEF-
1 in mediating nuclear-localization of β-catenin was confirmed using both knockdown 
and overexpression approaches. LEF-1 contains a nuclear localization sequence 
and is known to shuttle between cytoplasmic and nuclear compartments.42 This 
suggests LEF-1 could serve as a cytosolic-nuclear chaperone for β-catenin, however 
the high nuclear:cytosol ratio of LEF-1 expression observed in Wnt-responsive cells 
(K562 and HEL) would be more consistent with LEF-1 serving as a nuclear retention 
factor for β-catenin, as has been demonstrated previously for other Wnt signaling 
components.34 This is the first evidence of LEF-1 contributing to β-catenin nuclear-
localization capacity in human myeloid leukemia cells, however our data cannot 
exclude the role of other factors in this process. Nuclear export mechanisms may 
also be influential in limiting nuclear accumulation of β-catenin in Wnt-unresponsive 
cell lines. In particular, RanBP1 was an interacting partner detected for β-catenin in 
ML-1 nuclei but absent in K562/HEL nuclei and may warrant further study given the 
documented role for RanBP3 in mediating β-catenin export.43 Two factors recently 
implicated in nuclear β-catenin regulation including RAPGEF544 and Twa1,45 were 
not detected in our analyses, suggesting their interaction with β-catenin is context-
dependent.   
 
A strong correlation between the relative levels of nuclear localized β-catenin and 
LEF-1 was identified in primary AML samples suggesting this relationship may have 
clinical relevance. Indeed, expression of constitutively active LEF-1 in HSPCs 
induced AML in mice,38 and LEF-1 expression promotes the survival of myeloid 
leukemia cell lines.46 In our study, we observed significantly inhibited growth in K562 
and HEL cells harboring LEF-1 knockdown (Figure 6C). Given the adverse prognosis 
of nuclear β-catenin in AML5 and recent studies demonstrating its therapeutic merit 
in AML models,47-49 LEF-1 represents an attractive target in myeloid leukemia 
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through also inhibiting β-catenin nuclear localization. Small molecule inhibitors of β-
catenin: TCF/LEF interaction are in development and have shown efficacy in 
leukemia treatment.50-52 It would be interesting to observe if this efficacy is partly 
driven by reducing the level of nuclear β-catenin in leukemia cells. This study 
focused on the role of LEF-1 driving aberrant β-catenin nuclear-localization in 
myeloid leukemia however, given the frequency of Wnt/β-catenin dysregulation in 
human cancer, this axis could be active in other malignancies. 
 
We also observed that LEF-1 is proteolytically degraded in Wnt-unresponsive 
leukemia cells resulting in the emergence of short-form LEF-1 proteins (25-30kDa). 
These were smaller than the 38kDa transcriptional isoforms previously reported to 
derive from alternative splicing or alternative promoter usage39,53 which serve as 
dominant-negative inhibitors of Wnt signaling because they lack the β-catenin 
binding domain necessary to initiate transcription.39 In contrast, the proteolytic 
fragments observed in this study retained β-catenin binding capacity (Figure 7A) and 
did not appear to have dominant-negative function (Wnt targets were still activated; 
Figure 6C and D). Under the conditions of the experiment, however, where LEF-1 is 
being overexpressed, the abundance of these fragments may have a dominant effect 
on β-catenin retention in the nucleus, whereas under normal circumstances, it is 
likely that degradation serves to remove LEF-1 and suppress the nuclear retention of 
β-catenin. This post-translational regulation of LEF-1 has parallels with embryonic 
stem cells where proteolytic cleavage of TCF-3 (TCF7L1), a closely related family 
member, removes it from target genes when differentiation signals trigger the 
suppression of Wnt signaling.54 In leukemia cells this proteolytic cleavage could be 
mediated by NLK (Nemo-like kinase) which binds the E3 ubiquitin-ligase NARF (NLK 
associated RING finger protein) and reportedly induces ubiquitylation (and 
proteasomal degradation) of LEF-1 in cooperation with the E2 conjugating enzyme 
E2-25K;55 a mechanism previously reported to be active in leukemia cells.56 
 
In summary, our study has made three key findings; firstly, the generation of the first 
β-catenin interactomes in leukemia cells; secondly, the characterization of LEF-1 as 
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a regulator of nuclear β-catenin localization in leukemia and finally, the 
demonstration of post-transcriptional proteolytic degradation mechanisms for 
controlling LEF-1 expression in myeloid leukemia cells. 
Disclosure of Potential Conflicts of Interest 
No conflict of interest declared. 
Author contributions 
RGM designed and performed experiments, analyzed data and wrote the 
manuscript. JR, MP and SD performed experiments, KH and MW performed 
proteomic analyses. AG developed co-IP methodology and provided manuscript 
advice. ADD, ACW and AB provided technical guidance and manuscript advice. MW 
provided experimental advice whilst AT and RLD provided project direction and co-
wrote the manuscript.  
Acknowledgements 
RGM is funded by a Kay Kendall Leukemia Fund (KKLF) Junior Fellowship 
(KKL1051), British Society for Haematology (BSH) Early Stage Research Start-up 
Grant (34725), and a Royal Society Research Grant (RG160682). JR is funded by 
Cancer Research Wales. AT and RLD received funding from a Bloodwise 
programme grant (13029). We are grateful to clinical staff, including Lizzy Palmer 
and Julia Wolf, at the Bristol Royal Hospital for Children (BRHC) and the Bristol 
Haematology and Oncology Centre (BHOC) respectively, for collection of AML 
patient samples and supplying associated clinical data. We are also grateful to the 
patients and their families who gave permission for their cells to be used for 
research.  
 
References 
1. Nusse R, Clevers H. Wnt/beta-Catenin Signaling, Disease, and Emerging 
Therapeutic Modalities. Cell. 2017;169(6):985-999. 
2. Li VS, Ng SS, Boersema PJ, et al. Wnt signaling through inhibition of beta-
catenin degradation in an intact Axin1 complex. Cell. 2012;149(6):1245-1256. 
Morgan et al, 2019                           LEF-1 regulates β-catenin nuclear localization 
17 
 
3. Morgan RG, Ridsdale J, Tonks A, Darley RL. Factors affecting the nuclear 
localization of beta-catenin in normal and malignant tissue. J Cell Biochem. 
2014;115(8):1351-1361. 
4. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the 
Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene. 
2005;24(14):2410-2420. 
5. Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute 
myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. 
Leukemia. 2006;20(7):1211-1216. 
6. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is 
required for the development of leukemia stem cells in AML. Science. 
2010;327(5973):1650-1653. 
7. Zhao C, Blum J, Chen A, et al. Loss of beta-catenin impairs the renewal of 
normal and CML stem cells in vivo. Cancer Cell. 2007;12(6):528-541. 
8. Muller-Tidow C, Steffen B, Cauvet T, et al. Translocation products in acute 
myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell 
Biol. 2004;24(7):2890-2904. 
9. Coluccia AM, Vacca A, Dunach M, et al. Bcr-Abl stabilizes beta-catenin in 
chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 
2007;26(5):1456-1466. 
10. Griffiths EA, Golding MC, Srivastava P, et al. Pharmacological targeting of 
beta-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica. 
2015;100(2):e49-52. 
11. Morgan RG, Pearn L, Liddiard K, et al. gamma-Catenin is overexpressed in 
acute myeloid leukemia and promotes the stabilization and nuclear localization of 
beta-catenin. Leukemia. 2013;27(2):336-343. 
12. Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJ. Wnt signaling strength 
regulates normal hematopoiesis and its deregulation is involved in leukemia 
development. Leukemia. 2012;26(3):414-421. 
13. Morgan RG, Mortensson E, Legge DN, et al. LGR5 expression is regulated by 
EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. Br J 
Cancer. 2018;118(4):558-565. 
14. Morey L, Brenner C, Fazi F, et al. MBD3, a component of the NuRD complex, 
facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 
2008;28(19):5912-5923. 
15. Boukarabila H, Saurin AJ, Batsche E, et al. The PRC1 Polycomb group 
complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 
2009;23(10):1195-1206. 
16. Kim JJ, Khalid O, Vo S, Sun HH, Wong DT, Kim Y. A novel regulatory factor 
recruits the nucleosome remodeling complex to wingless integrated (Wnt) signaling 
gene promoters in mouse embryonic stem cells. J Biol Chem. 2012;287(49):41103-
41117. 
17. Chiacchiera F, Rossi A, Jammula S, et al. Polycomb Complex PRC1 
Preserves Intestinal Stem Cell Identity by Sustaining Wnt/beta-Catenin 
Transcriptional Activity. Cell Stem Cell. 2016;18(1):91-103. 
18. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression 
predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118(10):2857-
2867. 
19. Kaeda J, Ringel F, Oberender C, et al. Up-regulated MSI2 is associated with 
more aggressive chronic myeloid leukemia. Leuk Lymphoma. 2015;56(7):2105-2113. 
Morgan et al, 2019                           LEF-1 regulates β-catenin nuclear localization 
18 
 
20. Li Z, Jin H, Mao G, Wu L, Guo Q. Msi2 plays a carcinogenic role in 
esophageal squamous cell carcinoma via regulation of the Wnt/beta-catenin and 
Hedgehog signaling pathways. Exp Cell Res. 2017;361(1):170-177. 
21. Helsmoortel HH, De Moerloose B, Pieters T, et al. LIN28B is over-expressed 
in specific subtypes of pediatric leukemia and regulates lncRNA H19. 
Haematologica. 2016;101(6):e240-244. 
22. Zhou J, Bi C, Ching YQ, et al. Inhibition of LIN28B impairs leukemia cell 
growth and metabolism in acute myeloid leukemia. J Hematol Oncol. 
2017;10(1):138. 
23. Tu HC, Schwitalla S, Qian Z, et al. LIN28 cooperates with WNT signaling to 
drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes 
Dev. 2015;29(10):1074-1086. 
24. Yassin ER, Abdul-Nabi AM, Takeda A, Yaseen NR. Effects of the NUP98-
DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase 
motif. Leukemia. 2010;24(5):1001-1011. 
25. Gu TL, Mercher T, Tyner JW, et al. A novel fusion of RBM6 to CSF1R in 
acute megakaryoblastic leukemia. Blood. 2007;110(1):323-333. 
26. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and 
MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 
2001;28(3):220-221. 
27. Wang Y XW, Wei SM, Chen XM, Wei L, Tian RH, Meng Li, Xiao BR, Wu PX, 
Yu YH. Highly expressed DDX10 promotes hepatocellular carcinoma cell 
proliferation through Wnt/β-catenin signaling. Int J Clin Exp Pathol. 2017;10(5):6047-
6053. 
28. Niu C, Zhang J, Breslin P, Onciu M, Ma Z, Morris SW. c-Myc is a target of 
RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and 
megakaryocyte development. Blood. 2009;114(10):2087-2096. 
29. Naudin C, Hattabi A, Michelet F, et al. PUMILIO/FOXP1 signaling drives 
expansion of hematopoietic stem/progenitor and leukemia cells. Blood. 
2017;129(18):2493-2506. 
30. Lee KY, Chan KY, Tsang KS, et al. Ubiquitous expression of MAKORIN-2 in 
normal and malignant hematopoietic cells and its growth promoting activity. PLoS 
One. 2014;9(3):e92706. 
31. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and 
oncogene: the WT1 story. Leukemia. 2007;21(5):868-876. 
32. Jamieson C, Sharma M, Henderson BR. Regulation of beta-catenin nuclear 
dynamics by GSK-3beta involves a LEF-1 positive feedback loop. Traffic. 
2011;12(8):983-999. 
33. Simcha I, Shtutman M, Salomon D, et al. Differential nuclear translocation and 
transactivation potential of beta-catenin and plakoglobin. J Cell Biol. 
1998;141(6):1433-1448. 
34. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-
catenin is regulated by retention. J Cell Sci. 2006;119(Pt 7):1453-1463. 
35. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin 
with the transcription factor LEF-1. Nature. 1996;382(6592):638-642. 
36. Davies ML, Roberts GT, Stuart N, Wakeman JA. Analysis of a panel of 
antibodies to APC reveals consistent activity towards an unidentified protein. Br J 
Cancer. 2007;97(3):384-390. 
37. Daud SS. The Role of WNT Transcription Factor TCF7L2 in Acute Myeloid 
Leukaemia. Cardiff University. 2014. 
Morgan et al, 2019                           LEF-1 regulates β-catenin nuclear localization 
19 
 
38. Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central 
transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med. 
2008;205(3):515-522. 
39. Hovanes K, Li TW, Munguia JE, et al. Beta-catenin-sensitive isoforms of 
lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 
2001;28(1):53-57. 
40. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. 
Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or 
lymphopoiesis. Blood. 2008;111(1):160-164. 
41. Trompouki E, Bowman TV, Lawton LN, et al. Lineage regulators direct BMP 
and Wnt pathways to cell-specific programs during differentiation and regeneration. 
Cell. 2011;147(3):577-589. 
42. Prieve MG, Guttridge KL, Munguia JE, Waterman ML. The nuclear 
localization signal of lymphoid enhancer factor-1 is recognized by two differentially 
expressed Srp1-nuclear localization sequence receptor proteins. J Biol Chem. 
1996;271(13):7654-7658. 
43. Hendriksen J, Fagotto F, van d, V, van SM, Noordermeer J, Fornerod M. 
RanBP3 enhances nuclear export of active (beta)-catenin independently of CRM1. J 
Cell Biol. 2005;171(5):785-797. 
44. Griffin JN, Del Viso F, Duncan AR, et al. RAPGEF5 Regulates Nuclear 
Translocation of beta-Catenin. Dev Cell. 2018;44(2):248-260.e4. 
45. Lu Y, Xie S, Zhang W, et al. Twa1/Gid8 is a beta-catenin nuclear retention 
factor in Wnt signaling and colorectal tumorigenesis. Cell Res. 2017;27(12):1422-
1440. 
46. Skokowa J, Cario G, Uenalan M, et al. LEF-1 is crucial for neutrophil 
granulocytopoiesis and its expression is severely reduced in congenital neutropenia. 
Nat Med. 2006;12(10):1191-1197. 
47. Stoddart A, Wang J, Hu C, et al. Inhibition of WNT signaling in the bone 
marrow niche prevents the development of MDS in the Apc(del/+) MDS mouse 
model. Blood. 2017;129(22):2959-2970. 
48. Li L, Sheng Y, Li W, et al. beta-Catenin Is a Candidate Therapeutic Target for 
Myeloid Neoplasms with del(5q). Cancer Res. 2017;77(15):4116-4126. 
49. Jiang X, Mak PY, Mu H, et al. Disruption of Wnt/beta-Catenin Exerts 
Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute 
Myeloid Leukemia. Clin Cancer Res. 2018;24(10):2417-2429. 
50. Dandekar S, Romanos-Sirakis E, Pais F, et al. Wnt inhibition leads to 
improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J 
Haematol. 2014;167(1):87-99. 
51. Minke KS, Staib P, Puetter A, et al. Small molecule inhibitors of WNT 
signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J 
Haematol. 2009;82(3):165-175. 
52. Gandhirajan RK, Staib PA, Minke K, et al. Small molecule inhibitors of 
Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia 
cells in vitro and in vivo. Neoplasia. 2010;12(4):326-335. 
53. Hovanes K, Li TW, Waterman ML. The human LEF-1 gene contains a 
promoter preferentially active in lymphocytes and encodes multiple isoforms derived 
from alternative splicing. Nucleic Acids Res. 2000;28(9):1994-2003. 
54. Shy BR, Wu CI, Khramtsova GF, et al. Regulation of Tcf7l1 DNA binding and 
protein stability as principal mechanisms of Wnt/beta-catenin signaling. Cell Rep. 
2013;4(1):1-9. 
Morgan et al, 2019                           LEF-1 regulates β-catenin nuclear localization 
20 
 
55. Yamada M, Ohnishi J, Ohkawara B, et al. NARF, an nemo-like kinase (NLK)-
associated ring finger protein regulates the ubiquitylation and degradation of T cell 
factor/lymphoid enhancer factor (TCF/LEF). J Biol Chem. 2006;281(30):20749-
20760. 
56. Gupta K, Kuznetsova I, Klimenkova O, et al. Bortezomib inhibits STAT5-
dependent degradation of LEF-1, inducing granulocytic differentiation in congenital 
neutropenia CD34(+) cells. Blood. 2014;123(16):2550-2561. 
 
Figure Legends 
 
Figure 1. Myeloid leukemia cell lines exhibit a heterogeneous response to Wnt 
stimulation. (A) Representative immunoblots showing total β-catenin subcellular-
localization in myeloid cells following CHIR99021 treatment (GSK3β inhibitor). Lamin 
A/C and α-tubulin indicate the purity/loading of the nuclear (N) and cytosol (C) 
fractions respectively. (B) Representative flow cytometric histograms showing 
intensity of the TCF-dependent expression of YFP from the ‘β-catenin activated 
reporter’ (BAR) reporter, or negative control ‘found unresponsive β-catenin activated 
reporter’ (fuBAR) control (containing mutated promoter binding sites) following 
treatment with CHIR99021/vehicle control (DMSO) as above. (C) Summary showing 
the relative percentage nuclear β-catenin localization (as a proportion of the total) 
induced in myeloid cell lines upon CHIR99021 treatment. (D) Summary showing the 
median fluorescence intensity generated from the BAR/fuBAR reporters in myeloid 
cell lines treated ± CHIR99021. Statistical significance is denoted by *P<0.05 and 
****P<0.0001, ns=not significant.  
Figure 2. Experimental strategy for analysis of β-catenin interaction partners in 
myeloid leukemia cell lines. (A) Wnt-responsive K562/HEL cells and Wnt-
unresponsive cells ML-1 cells were treated with CHIR99021 to stabilize β-catenin 
prior to cytosolic/nuclear fractionation. From these fractions, either an IgG or β-
catenin (β-cat) co-IP was performed generating 8 samples which were each TMT 
labelled with a unique isobaric mass tag. All samples were pooled, fractionated, 
cleaned and analysed by mass spectrometry. Mass intensities from each tag report 
the relative peptide abundance in each sample. Quantitative fold-enrichment of β-
catenin co-IP was obtained by comparison with fraction-matched IgG co-IP control. 
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Three biological replicates were performed on each cell line. (B) Representative 
immunoblots showing the efficiency of total β-catenin co-IP performed from the 
cytosol or nuclear fractions of SW620 cells and HEL cells. Detection of the known 
interaction partner TCF-4 was used to assess binding partner efficiency. ID= 
immunodepleted lysate. β-Catenin arrows represent full-length/degradation 
intermediates; TCF-4 arrows indicate 58/79kDa transcriptional isoforms. 
Figure 3. Proteomics analyses reveal contrasting β-catenin interaction profiles 
between Wnt-responsive and Wnt-unresponsive leukemia cell lines. Scatter 
plots showing β-catenin protein interactions detected in (A) K562 cytosolic, (B) K562 
nuclear, (C) ML1 cytosolic and (D) ML1 nuclear fractions. Vertical dashed red line 
indicates the threshold for 2-fold change in protein binding at log2 (=1) relative to IgG 
co-IP. Horizontal red line represents threshold for significant interactions at p=0.05 
on log10 scale (=1.3). Highlighted red dots indicate statistically significant interactions 
and green highlighted events/labels indicate known interactions/associations for β-
catenin. Remaining black dots represent other proteins detected in the MS analysis; 
see also Supplementary MS Data Excel sheets. Fold change values less than 0 are 
not shown because these likely represent contaminants (see Supplementary MS 
Data Excel sheets). 
Figure 4. Mass spectrometric analyses identify putative novel interaction 
partners for β-catenin in myeloid leukemia cell lines. Bar graphs summarising 
the average fold change in protein binding (relative to matched IgG co-IP) for novel, 
significant β-catenin interactions observed in (A) K562 cytosolic, (B) K562 nuclear, 
(C) ML1 cytosolic, and (D) ML1 nuclear fractions. Significant proteins only are shown 
(red dots in Figure 2 panels) with a frequency on the CRAPome database of ≤10% 
and known interactions were removed. Red asterisks represent proteins of particular 
significance to myeloid leukemias and/or Wnt signaling (see results). Proteins are 
ranked along X-axis according to statistical significance (left = most significant); see 
also Supplementary Table S2. 
Figure 5. Correlation between nuclear LEF-1 and nuclear β-catenin in leukemia 
cell lines and primary AML samples. (A) Representative immunoblot screen of 
myeloid leukemia cell lines showing the relative cytoplasmic (C) and nuclear (N) 
abundance of candidate proteins influencing β-catenin nuclear localization detected 
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by MS. SW620 colorectal cells were used as a positive control. TCF-4 arrows 
indicate 58/79kDa transcriptional isoforms. (B) Representative immunoblots showing 
the cytosolic and nuclear expression of both LEF-1 and total β-catenin in primary 
AML patient samples. LEF-1 protein isoforms migrate as bands between 40-55kDa. 
Lamin A/C and GAPDH or α-tubulin were used to assess fractionation efficiency and 
equal protein loading. (C) Summary scatter plot showing correlation between relative 
percentage nuclear β-catenin localization and relative percentage nuclear LEF-1 
localization in primary AML patient blasts.  
Figure 6. Modulation of LEF-1 expression affects relative nuclear β-catenin 
level. (A) Representative immunoblots showing the level and subcellular localization 
of total β-catenin and LEF-1 protein in K562 and HEL cells in response to 
control/LEF1 shRNA ± CHIR99021 treatment. Shorter 6hr CHIR99021 treatments 
were used for these cells to minimise the LEF-1 expression induced through Wnt 
stimulation. (B) Summary graph showing the relative percentage nuclear β-catenin 
localization induced upon 6hr CHIR99021 treatment of K562 or HEL cells ± 
control/LEF-1 shRNA. (C) Effect of LEF1 shRNA on the proliferation of K562 and 
HEL at different concentrations of serum after 24, 48 and 72 hours. (D) 
Representative immunoblots showing the level and subcellular localization of total β-
catenin and LEF-1 protein in ML-1 and U937 cells in response to control/LEF1 
overexpression (o/e) ± 16hr CHIR99021 treatment. The positions of full-length (FL) 
and short-forms (SF) of LEF-1 protein on the blot are indicated by arrows. Lamin A/C 
and α-tubulin were used to assess fraction purity and protein loading. (E) Summary 
graph showing the relative percentage nuclear β-catenin localization induced upon 
CHIR99021 treatment of ML-1 and U937 cells for 16hr ± control/LEF1 
overexpression. Statistical significance is denoted by *P<0.05 and **P<0.01. 
Figure 7. Modulation of LEF-1 expression affects downstream Wnt signalling. 
(A) Representative flow cytometric histograms showing intensity of the TCF reporter 
(BAR) in K562 and HEL cells treated with control/LEF1 shRNA ± CHIR99021. (B) 
Summary data showing the median fluorescence intensity generated from the BAR 
reporter in K562 and HEL cells treated with control/LEF1 shRNA ± CHIR99021. (C) 
Representative immunoblots showing expression of known Wnt target proteins 
survivin, c-MYC and cyclinD1 in ML-1 and U937 cells in response to control/LEF1 
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overexpression ± CHIR99021. Lamin A/C and α-tubulin were used to assess fraction 
purity and protein loading. (D) Summary data showing the relative fold-change in 
nuclear protein expression of classic Wnt targets survivin, c-MYC and cyclinD1 in 
CHIR99021 treated ML1 and U937 cells overexpressing LEF1. Dashed line 
represents relative level (=1) present in nuclei of CHIR99021-treated ML1 and U937 
cells expressing control plasmid. Statistical significance is denoted by *P<0.05, 
**P<0.01 and ***P<0.001, ns=not significant. 
Figure 8. Short-form LEF-1 is proteolytically-derived and is capable of β-
catenin binding. (A) Representative immunoblot showing total β-catenin co-IP from 
cytosolic and nuclear fraction of LEF1-overexpressing U937 cells. Total β-Catenin 
and LEF-1 protein levels are shown. ID= immunodepleted lysate.  Representative 
immunoblot showing LEF-1 protein levels in (B) K562 control and (C) U937-LEF1 
nuclear lysates ± protease inhibitor cocktail (PIC) during time course incubation at 
37°C. (D) Representative immunoblots showing LEF-1 protein levels in K562 control 
nuclear lysate after mixing with U937 control whole cell lysate (1:1 protein 
concentration) ± PIC during time course incubation at 37°C. Nuclear lamin A/C 
detection was used to assess protein loading. 
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Supplementary Table S1. Clinical characteristics of AML/MDS patient diagnostic/relapse samples used in this study. 
 
Patient 
no. 
Age (at 
diagnosis) 
Sex WBC 
count 
(x109/L) 
Sample 
type 
Secondary 
disease 
(Y/N) 
Genetic information Other clinical information 
1 76 F 389 LP N Normal karyotype, NPM1+, FLT3+ n/a 
2 4 M n/a BM n/a n/a n/a 
3 10 F n/a BM n/a n/a Deceased 
4 n/a n/a >200 PB Y n/a Post-allogeneic transplant. M0/1 
(previously diagnosed with M3 10 
years previous) 
5 6 M n/a BM Y n/a Relapse 
6 17 M n/a BM Y n/a Post-BMT for AML following 2 
relapses. Deceased 
7 6 M 70.7 n/a Y n/a Secondary to Ewings Sarcoma. 
Myelomonocytic morphology. 
Deceased. 
8 14 F 7.6 BM N MLL rearrangement. Karyotype: 
46,XX,ins(10;11)(q11.2;q23.1q23.3).ish 
ins(10;11)?inv(11)(q23.3)(5’MLL+)(q23.1)(3’MLL+) 
BMT for high-risk AML 
9 10 M 5.7 BM N Monosomy 7 secondary to GATA2 deficiency BMT for MDS (Barth Syndrome) 
10 43 M 16.1 BM N Normal karyotype n/a 
11 8 M 4.2 BM N t(8;21)(q22;q22) RUNX-RUNX1T1 Phenotype fits WHO criteria of MPAL. 
MRD negative post treatment course 1 
and 2 
12 4 M 3.2 BM N t(10;11)(p11.2;q23) KMT2A-MLLT10 High risk cytogenetics. BMT. 
13 14 F 14.7 PB N t(8;21)(q22;q22) RUNX-RUNX1T1 MRD negative post treatment course 1 
and 2 
14 5 M 1.6 BM N n/a M5. Deceased. 
15 2 M 15.0 BM N t(8;21)(q22;q22) RUNX-RUNX1T1 n/a 
16 8 F n/a BM N n/a M4/5. Deceased. 
17 7 F 34.4 BM Y MLL rearrangement t(9;11) M5a morphology. BMT following 
relapse. Deceased 
18 n/a n/a n/a LP n/a n/a n/a 
19 6 F 20.6 BM N Normal karyotype n/a 
20 64 F 13.3 BM N Normal karyotype AML with underlying MDS like changes 
21 13 F 91.9 BM Y High Risk Relapsed AML secondary to Rhabdoid 
tumour. Deceased 
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22 15 F 6.5 BM N MLL (KMT2A) rearrangement, t(10;11)(p11-p14,q23), MLL-
MLLT10 
MRD detected post treatment course 1 
23 4 F 2.6 BM N Normal karyotype, NPM1+ MRD neg 
24 7 M 3.5 BM N t(8;21)(q22;q22) RUNX-RUNX1T1  
25 17 M n/a BM N t(15;17)(q24;q12)  
26 2 M 2.4 BM N t(9;11)(p22;q23), t(11;21)(q23;q8)  
27 14 F 2.1 BM N -7 BMT 
28 11 M n/a BM N n/a BMT for MDS. Deceased 
29 7 F n/a BM N MPAL, 46XX, del5q, abnormal 21  
30 4mo M 5.1 BM N t(9;11) BMT 
31 10 F 1.4 BM N n/a  
32 9 M 13.0 BM N Pericentric inversion of chromosome 16 90% blasts in BM, 73% blasts in PB  
33 6 M n/a BM N n/a  
 
BM = Bone marrow 
PB = Peripheral blood 
LP = Leukapheresis 
MRD = Minimal residual disease 
BMT = Bone marrow transplant 
AML= Acute myeloid leukemia 
MDS= Myelodysplastic syndrome  
MPAL= Mixed phenotype acute leukemia 
MLL = Mixed-lineage leukemia 
NPM1 = Nucleophosmin 
FLT3 = Fms-like tyrosine kinase 3 
RUNX1 = Runt-related transcription factor 1 
GATA2 = GATA Binding Protein 2 
WHO = World Health Organisation 
n/a = not available
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Supplementary Figure S1. Myeloid cell line viability and b-catenin phosphorylation variant 
expression in response to GSK3 inhibition. (A) Representative flow cytometric pseudocolor plots 
showing propidium staining for K562, HEL, ML-1 and U937 cells following 16hr 5µM CHIR99021 
treatment. Percentage of events falling into PI negative gate (viable) are given in upper right of each 
plot. (B) Summary showing the percentage cell viability for each myeloid cell line following 16hr 5µM 
CHIR99021 treatment. (C) Representative immunoblots showing total b-catenin, active (non-
phosphorylated) b-catenin and phosphorylated b-catenin (Ser33/37/Thr41) subcellular-localization 
in myeloid cells following CHIR99021 treatment (GSK3b inhibitor). Lamin A/C and a-tubulin indicate 
the purity/loading of the nuclear (N) and cytosol (C) fractions respectively. Data represents mean±1 
SD, n=3, ns=not significant.  
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Supplementary Figure S2. Myeloid leukemia cell lines exhibit a heterogeneous response to 
Wnt stimulation with Wnt3a. (A) Representative flow cytometric histograms showing intensity of 
the TCF-dependent expression of YFP from the ‘b-catenin activated reporter’ (BAR) reporter, or 
negative control ‘found unresponsive b-catenin activated reporter’ (fuBAR) control (containing 
mutated promoter binding sites) following treatment with rWnt3a/vehicle control (PBS/0.1% BSA) 
for 16hr.  (B) Summary showing the median fluorescence intensity generated from the BAR/fuBAR 
reporters in myeloid cell lines treated ± rWnt3a. Data represents mean±1 SD, statistical significance 
is denoted by **P<0.01 and ns=not significant. 
 
 
 
 
 
 
 
 
Morgan et al, 2019                                                            LEF-1 regulates β-catenin nuclear localization 
 
 
 
 
 
 
 
 
 
Supplementary Figure S3. Proteomics analyses reveal rich b-catenin interaction networks in 
Wnt-responsive HEL cells. Scatter plots showing summary of b-catenin protein interactions 
detected in HEL (A) cytosolic, and (B) nuclear fractions (n=3). Vertical dashed red line indicates the 
threshold for 2-fold change in protein binding at log2 (=1) relative to IgG Co-IP. Horizontal red line 
represents threshold for significant interactions at p=0.05 on log10 scale (=1.3). Highlighted red dots 
indicate all statistically significant interactions, blue dot indicates position of b-catenin bait and green 
highlighted events/labels indicate known enriched interactions/associations for b-catenin. 
Remaining black dots represent other proteins detected in the MS analysis. Fold change values less 
than 0 are not shown because these likely represent contaminants (see Supplementary material). 
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Supplementary Table S2. List of novel b-catenin interactions observed in K562 and ML1 cytosolic and 
nuclear fractions. Significant proteins only are shown, and specificity was defined as proteins detected in 
10% or less of the 411-affinity purified mass spectrometry datasets present in the CRAPome database. 
Known interactions were removed from the analysis. Proteins are ranked according to statistical significance 
of protein binding. Threshold for 2-fold change in protein binding (relative to IgG Co-IP) at log2 = 1, whilst 
threshold for significant interactions at p=0.05 on log10 scale = 1.3. 
 
Significance of protein 
binding (-Log10 t-test p 
value) 
Fold change in 
protein binding 
(Log2) 
Gene name CRAPome frequency 
(/411) 
K562 Cytosol 
3.77 3.01 CPEB4 1 
2.95 1.52 DDX20 40 
2.78 1.95 MRPS17 11 
2.58 3.03 PRKRA 23 
2.42 1.78 IGHMBP2 8 
2.35 0.41 APOBEC3B 9 
2.25 2.13 MRPS23 21 
2.22 1.99 TRIM25 29 
2.09 0.72 ABCF2 24 
2.08 2.30 DHX36 23 
2.07 0.56 MRPL1 13 
2.06 1.85 FASTK 0 
2.01 2.78 ZC3H7A 5 
2.01 1.89 PPHLN1 32 
1.95 1.62 EIF2AK2 14 
1.93 0.98 FLJ13612 24 
1.91 1.02 MRPS15 15 
1.89 2.07 UPF1 35 
1.87 1.08 MRPL11 11 
1.87 0.33 DDX24 40 
1.86 1.42 ZC3H7B 2 
1.82 2.06 MRPL2 22 
1.81 1.37 ZNF346 2 
1.78 1.48 MRPL27 14 
1.74 0.69 MBD3 32 
1.74 0.46 NOL11 25 
1.70 1.01 TOE1 21 
1.69 1.88 MSI2 13 
1.68 0.96 XRN1 26 
1.62 2.39 AP2M1 21 
1.61 3.12 ZCCHC3 8 
1.61 1.18 MRPS22 32 
1.58 2.57 DROSHA 10 
1.57 0.36 FYTTD1 13 
1.53 2.73 MRPL15 13 
1.53 0.46 NXF2B 0 
1.51 1.19 FAM83A 0 
1.51 2.09 PURA 27 
1.46 0.74 HNRNPLL 21 
1.43 0.66 PNAS 3 34 
1.43 2.00 PCM1 31 
1.43 1.17 APOBEC3F 17 
1.41 1.64 CELF1 10 
1.40 1.26 LARP1B 36 
1.37 1.72 BMP2K 0 
1.36 1.98 MRPS34 24 
1.35 1.42 RBM45 2 
1.34 0.61 ASCC3 39 
1.33 2.60 STAU2 32 
1.32 2.27 AP2A1 24 
1.31 2.14 AP2M1 21 
1.31 1.37 RBM7 23 
1.30 0.68 WDR76 8 
1.28 3.01 APOBEC3G 0 
1.27 1.51 MRPS2 19 
1.26 1.66 ARHGAP21 21 
1.26 1.76 DAP3 41 
K562 Nucleus 
2.17 0.47 LIN28B 10 
2.06 0.42 DDX24 40 
2.01 0.58 ZCCHC9 2 
1.96 0.71 UTP20 12 
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1.86 0.28 PRC1 22 
1.81 0.48 MRPS24 2 
1.65 0.50 POP1 40 
1.61 0.56 INTS6 1 
1.60 0.27 ABCF2 24 
1.56 0.61 DECR1 15 
1.54 1.58 RBM45 2 
1.52 1.35 NCOA5 19 
1.50 0.59 UTP3 23 
1.45 0.54 DAP3 41 
1.41 0.51 NOL9 34 
1.38 0.34 RRP1B 21 
1.35 0.61 MYBBP1A 3 
1.32 0.48 HNRPUL1 0 
1.30 0.89 HNRNPH1 30 
1.30 0.41 DDX10 14 
1.27 0.39 GNL2 32 
1.26 0.42 MBD3 13 
1.26 0.29 EXOSC9 2 
1.25 0.29 TIMM21 0 
ML1 Cytosol 
2.62 2.56 KRT34 28 
2.60 0.82 PPIF 28 
2.58 1.14 CLTB 14 
2.12 0.30 ADRBK1 0 
1.79 0.43 ATP6V1E1 16 
1.75 0.52 NXF1 38 
1.55 0.43 RBM15 40 
1.52 0.60 PIK3R1 5 
1.44 0.28 RAB5B 40 
1.41 0.39 HMGN5 9 
1.32 1.07 CENPV 26 
1.26 1.22 FABP5 38 
ML1 Nucleus 
2.41 0.06 INPP5D 0 
1.79 0.92 PNP 36 
1.44 0.40 TMX1 23 
1.43 0.18 RBM15 40 
1.42 0.31 HBS1L 32 
1.41 0.75 CDV3 26 
1.34 0.30 BUD31 28 
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Supplementary Figure S4. Mass spectrometric analyses identify putative novel interaction 
partners for b-catenin in HEL cells. Bar graphs summarising the average fold change in protein 
binding (relative to matched IgG co-IP) for novel b-catenin interactions observed in HEL (A) cytosolic 
and (B) nuclear fractions. Significant proteins only are shown (red dots in Supplementary Figure S1 
panels) with a frequency on the CRAPome database of ≤10% and known interactions were 
removed. Red asterisks represent proteins of particular significance to myeloid leukemias and/or 
Wnt signaling (discussed further in results section). Proteins are ranked along X-axis according to 
statistical significance (left = most significant); see also Supplementary Table S3. 
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Supplementary Table S3. List of novel b-catenin interactions observed in HEL cytosolic and nuclear 
fractions. Significant proteins only are shown, and specificity was defined as proteins detected in 10% or 
less of the 411-affinity purified mass spectrometry datasets present in the CRAPome database. Known 
interactions were removed from the analysis. Proteins are ranked according to statistical significance of 
protein binding. Threshold for 2-fold change in protein binding (relative to IgG Co-IP) at log2 =1, whilst 
threshold for significant interactions at p=0.05 on log10 scale =1.3. 
 
Significance of protein 
binding (-Log10 t-test p 
value) 
Fold change in 
protein binding 
(Log2) 
Gene name CRAPome frequency (/411) 
HEL Cytosol 
3.42 1.44 AP2S1 1 
2.90 1.53 CELF2 4 
2.82 3.12 LARP4B 20 
2.48 2.91 USP10 35 
2.35 2.32 MAGOH 37 
2.28 2.96 KEAP1 30 
1.99 0.85 TRIM25 29 
1.96 0.44 FAM208A 37 
1.93 2.00 STAU2 32 
1.93 0.29 WDR43 27 
1.83 2.48 CLINT1 40 
1.81 0.29 NDNL2 0 
1.75 2.14 PUM2 22 
1.72 1.22 HELZ 9 
1.68 2.87 RNF214 2 
1.63 3.37 ATXN2 33 
1.59 2.50 AGO1 14 
1.58 2.39 UPF2 0 
1.53 1.22 RBFOX2 14 
1.52 2.81 PRKRA 23 
1.38 0.33 TMEM33 34 
1.37 0.68 DDX20 40 
1.36 1.70 AP2M1 21 
1.36 1.16 RBM4 33 
1.33 1.16 WDR75 15 
1.29 1.93 DHX36 23 
1.29 3.85 APOBEC3F 17 
1.28 1.28 MKRN2 3 
1.26 0.90 CDC2L2 39 
HEL Nuclear 
4.33 1.23 RBM6 25 
2.58 0.90 USP10 35 
2.41 0.99 CMSS1 6 
2.18 0.44 PDS5B 8 
2.13 1.10 WDR3 20 
2.08 0.46 WDR36 41 
1.98 0.64 BCAS2 40 
1.93 0.40 MAK16 13 
1.88 1.55 NCBP1 38 
1.86 1.39 MYEF2 16 
1.82 1.02 RNF214 2 
1.78 2.10 PPHLN1 32 
1.70 1.21 DDX51 10 
1.69 2.09 CDC40 15 
1.67 0.51 FAM208A 37 
1.65 1.83 MAGOH 37 
1.59 0.88 RPF2 27 
1.55 2.18 APOBEC3B 9 
1.48 0.51 RBM45 2 
1.47 0.84 RBM4 33 
1.46 1.21 APOBEC3G 0 
1.45 1.19 PLRG1 38 
1.42 0.84 IFI16 9 
1.38 1.71 NIP7 16 
1.36 1.26 KIAA0020 16 
1.34 0.57 NR2F2 4 
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1.34 1.58 USP36 26 
1.32 0.90 INTS12 14 
1.30 1.53 C17orf85 22 
1.30 1.18 ZCCHC9 2 
1.27 0.71 NDNL2 0 
1.27 0.81 ZNF22 2 
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Supplementary Figure S5. Proteomics analyses reveal b-catenin interaction with WT1 in 
myeloid leukemia cells. Scatter plots showing summary of b-catenin protein interactions detected 
in (A) K562 cytosolic, (B) K562 nuclear, (C) ML1 cytosolic, and (D) ML1 nuclear fractions. Vertical 
dashed red line indicates the threshold for 2-fold change in protein binding at log2 (=1) relative to 
IgG co-IP. Horizontal red line represents threshold for significant interactions at p=0.05 on log10 
scale (=1.3). Highlighted red dots indicate all statistically significant interactions, blue dot indicates 
position of b-catenin bait and green dot indicates position of WT1. Remaining black dots represent 
other proteins detected in the MS analysis. (E) Representative immunoblots showing b-catenin and 
WT1 protein level from b-catenin co-IPs pulled down from the cytosol or nucleus of SW620 or HEL 
cells (ID=immunodepleted). Note the absence of WT1 detection in SW620 fractions highlighting 
potential context dependence of interaction. 
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Supplementary Figure S6. Expression of b-catenin protein in pediatric AML samples. 
Immunoblot screen of 26 primary pediatric AML patient samples showing level of total cell b-catenin 
compared with normal bone marrow (BM) or peripheral blood mononuclear cells (PB MNC). * 
samples overexpressing b-catenin protein (~80%) versus levels observed in normal BM or PB MNC. 
Interestingly, we observed a much higher overall incidence of b-catenin protein overexpression 
amongst our pediatric AML cohort (Supplemental Figure S4) versus previous estimates for adult 
AML (~20-60%; see supplemental references).1 3 This is in keeping with a recent study which 
examined the molecular landscape of pediatric AML, and found a higher proportion of 
aberrations which impact Wnt signaling relative to adult AML.4 Mixed-lineage leukemia (MLL) gene 
rearrangements are also more prevalent in childhood AML and this model of leukemogenesis has 
been shown to require b-catenin for malignant transformation.5 7 Detection of b-actin was used to 
assess protein loading. 
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Supplementary Figure S7. Modulation of LEF-1 expression affects relative nuclear b-catenin 
level. (A) Immunoblots showing LEF-1 protein expression level in K562 cells following lentiviral 
transduction with a panel of 5 human LEF-1 targeted shRNAs (#1 = TRCN0000-020163, #2 = -
413476, #3 = -418104, #4= -428178 and #5= -428355). Since LEF-1 shRNA #5 exhibited optimal 
LEF-1 protein reduction, this was used preferentially through the study. (B) Immunoblots showing 
the level and subcellular localization of b-catenin in K562/HEL cells in response to an alternative 
LEF-1 shRNA (#3). (C) Immunoblots showing the level and subcellular localization of b-catenin in 
representative Wnt-responsive cells (K562; exhibiting LEF-1 knockdown) and Wnt-unresponsive 
cells (ML-1; exhibiting LEF-1 overexpression) following Wnt3a exposure. The positions of full-length 
(FL) and short-forms (SF) of LEF-1 protein on the blot are indicated by arrows. (D) Immunoblots 
showing the level and subcellular localization of b-catenin in PLB-985 and THP-1 cells in response 
to control/LEF1 overexpression (o/e) ± 16 hr CHIR99021 treatment. Lamin A/C and a-tubulin were 
used to assess fraction purity and protein loading. 
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Supplementary Figure S8. Modulation of LEF-1 expression affects downstream Wnt 
signalling. (A) Representative flow cytometric histograms showing intensity of the TCF reporter 
(BAR) in K562 and HEL cells treated with an alternative LEF1 shRNA (#3) ± CHIR99021. (B) 
Summary data showing the median fluorescence intensity generated from the BAR reporter in K562 
and HEL cells treated with an alternative LEF1 shRNA (#3) ± CHIR99021. (C) Representative flow 
cytometric histograms showing intensity of the BAR reporter in K562 and HEL cells treated with an 
alternative LEF1 shRNA (#3) ± rWnt3a. (D) Summary data showing the median fluorescence 
intensity generated from the BAR reporter in K562 and HEL cells treated with an alternative LEF1 
shRNA (#3) ± rWnt3a. Data represents mean±1 SD, statistical significance is denoted by **P<0.01, 
***P<0.001, ****P<0.0001 and ns=not significant. 
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Supplementary Figure S9. Short forms of LEF-1 protein are observed in CRC cell lines and 
primary AML samples. (A) Immunoblot screen of 14 colorectal adenoma or cancer cell lines 
showing abundance of different LEF-1 protein forms. The positions of full-length (FL), dominant-
negative isoforms (DN) and short-forms (SF) of LEF-1 protein are indicated by arrows. The loading 
control for this blot has previously been published elsewhere.8 (B) Extended immunoblots showing 
the cytosolic and nuclear expression of LEF-1 protein forms in the primary AML patient samples 
featured in Figure 5. Lamin A/C and a-tubulin were used to assess fractionation efficiency and equal 
protein loading. 
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Supplementary Methods 
Cross-linking of antibodies for co-immunoprecipitation  
For co-immunoprecipitation, 8µg of β-catenin (Clone 14)/IgG (Clone MOPC-31C) antibody (Becton 
Dickinson, Oxford, UK) was crosslinked to Protein G Dynabeads® (Thermo Fisher Scientific, 
Loughborough, UK) for 2h at room temperature. Following washing, bound β-catenin/IgG antibody 
was crosslinked to Protein G Dynabeads® in coupling buffer (0.2M triethanolamine (Sigma-Aldrich) 
in PBS with 0.01% Tween-20 (pH9), 20mM Dimethyl pimelimidate dihydrochloride (Sigma-Aldrich) 
for 1 h at room temperature. Following washing, crosslinked β-catenin/IgG antibody was quenched 
(50mM ethanolamine (Sigma-Aldrich) in PBS with 0.01% Tween-20) for 30min at room temperature, 
followed by washing in elution buffer (0.2M glycine (Sigma-Aldrich) pH2.5 with 0.01% Tween-20) to 
remove uncrosslinked antibody. 
 
TMT Labelling and High pH reversed-phase chromatography 
Immunoprecipitated samples (eight samples per experiment) were digested on the beads with 
trypsin (2.5µg trypsin; 37°C, overnight), labelled with Tandem Mass Tag (TMT) ten-plex reagents 
according to the manufacturer’s protocol (Thermo Fisher Scientific) and the labelled samples 
pooled. The pooled sample was evaporated to dryness, resuspended in 5% formic acid and then 
desalted using a SepPak cartridge according to the manufacturer’s instructions (Waters, Milford, 
Massachusetts, USA).  Eluate from the SepPak cartridge was again evaporated to dryness and 
resuspended in buffer A (20 mM ammonium hydroxide, pH 10) prior to fractionation by high pH 
reversed-phase chromatography using an Ultimate 3000 liquid chromatography system (Thermo 
Fisher Scientific).  In brief, the sample was loaded onto an XBridge BEH C18 Column (130Å, 3.5 
µm, 2.1 mm X 150 mm, Waters, UK) in buffer A and peptides eluted with an increasing gradient of 
buffer B (20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 60 min.  The resulting 
fractions were evaporated to dryness and resuspended in 1% formic acid prior to analysis by nano-
LC MSMS. 
 
Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nano-LC system in line with 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  In brief, peptides in 1% (v/v) 
formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). After 
washing with 0.5% (v/v) acetonitrile 0.1% (v/v) formic acid peptides were resolved on a 250 mm × 
75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 min 
organic gradient, using 7 gradient segments (1-6% solvent B over 1 min, 6-15% B over 58 min, 15-
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32% B over 58 min, 32-40% B over 5 min, 40-90% B over 1 min, held at 90% B for 6 min and then 
reduced to 1% B over 1 min) with a flow rate of 300 nl/min. Solvent A was 0.1% formic acid and 
Solvent B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-
electrospray ionization at 2.0kV using a stainless-steel emitter with an internal diameter of 30 μm 
(Thermo Scientific) and a capillary temperature of 275°C. All spectra were acquired using an 
Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 2.0 software (Thermo Scientific) 
and operated in data-dependent acquisition mode using an SPS-MS3 workflow. FTMS1 spectra 
were collected at a resolution of 120 000, with an automatic gain control (AGC) target of 200 000 
and a max injection time of 50ms. Precursors were filtered with an intensity threshold of 5000, 
according to charge state (to include charge states 2-7) and with monoisotopic precursor selection. 
Previously interrogated precursors were excluded using a dynamic window (60s +/-10ppm). The 
MS2 precursors were isolated with a quadrupole mass filter set to a width of 1.2m/z. ITMS2 spectra 
were collected with an AGC target of 10 000, max injection time of 70ms and CID collision energy 
of 35%. For FTMS3 analysis, the Orbitrap was operated at 50 000 resolution with an AGC target of 
50 000 and a max injection time of 105ms. Precursors were fragmented by high energy collision 
dissociation (HCD) at a normalized collision energy of 60% to ensure maximal TMT reporter ion 
yield.  Synchronous Precursor Selection (SPS) was enabled to include up to 5 MS2 fragment ions 
in the FTMS3 scan. 
 
Mass spectrometry Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo 
Scientific) and searched against the UniProt Human database  (134169 entries downloaded 
18/4/2016) using the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 10ppm, 
and MS/MS tolerance was set at 0.6Da.  Search criteria included oxidation of methionine (+15.9949) 
as a variable modification and carbamidomethylation of cysteine (+57.0214) and the addition of the 
TMT mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. Searches were 
performed with full tryptic digestion and a maximum of 1 missed cleavage was allowed.  The reverse 
database search option was enabled and all peptide data was filtered to satisfy false discovery rate 
(FDR) of 1%. 
 
b-Catenin and LEF-1 densitometry 
Densitometry was performed using ImageJ software v2.0.0-rc-43/1.51s (National Institutes of 
Health, Bethesda, MD, USA) and arbitrary densitometric units used to calculate relative nuclear b-
catenin/LEF-1 localization. Relative percentage nuclear localization was calculated by normalizing 
the b-catenin or LEF-1 protein level to the a-tubulin or lamin A/C protein level present in the 
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respective cytosolic or nuclear fraction, followed by calculation of the nuclear b-catenin or LEF-1 
present as a proportion of the total b-catenin or LEF-1 level. 
 
 
 
Supplementary MS data (see associated Excel file).  
 
Raw and processed tandem mass tag (TMT) mass spectrometry data obtained from b-catenin co-
IP’s from K562, HEL, ML-1 and SW620 cytoplasm and nuclear fractions. These data can also be 
found deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository with the dataset 
identifier PXD009305. Parameter definitions and data sheet types are explained within the first 
sheets of the excel file.  
